Newsletter

October 2, 2001

Volume IV, Issue 83

Email : info@otcjournal.com
URL : http://www.otcjournal.com

To OTC Journal Members:

Astralis/Hercules (OTC BB: HDVG) Development Group Update

We released our profile on Astralis/Hercules Development Group just after the market closed on Friday. The stock traded sideways yesterday on fairly strong volume, then dropped about $.40 near the end of the day. Click Here if you wish to read it.

We believe this is one of them most exciting situations we have ever found, and truly a huge opportunity for individual investors. Rarely does the the individual investor have the opportunity to invest in a pure new drug play of this magnitude. Breakthroughs like this are generally hidden within the larger scope of a major pharmaceutical company or bio-tech stock.

However, in the short term this stock is trading very poorly. Clearly there are core shareholders looking to raise cash or short sellers, which is to be expected in this market environment.

Below is an excerpt from the profile last Friday: You will note we cautioned everybody to only invest 25% to 50% of the dollars they would allocate for this exciting situation.

Recommended Trading Strategy

After reading our profile, if you find you agree with our conclusions, we would like to offer our opinion on a prudent investment strategy. Decide how many risk dollars you are prepared to commit to the investment, and start with only 25% to 50%. If you are opposed to risk read no further. This investment opportunity is not for you.

Over the next 60 days, more evidence should unfold concerning the potential for this new drug. This could come in the form of investments or alliances with major pharmaceutical names, which would act as confirmation of the commercial potential. As each of these events occur, the risk factor diminishes.

If you make additional purchases at higher prices, your average cost will still be below the market. If the stock has traded lower it will provide a more attractive entry level. This is only a suggested strategy; the choice is yours.

We knew there was a possibility things might not go well in the short term, hence our caution. In light of the the stock's poor performance in the short term, those who were only looking for a short term trade should probably take their loss and move on.

If you have a longer term outlook, wait for future developments which will include the closing of the Astralis purchase and potential alliances with major pharmaceutical companies.

If you invested for a quick trade, take your loss and get out. The stock does not look as if it wants to trade favorably in the short term. If you are interested in owning a piece of the future of Psoraxine wait for further developments to invest the remainder of your cash. We are expecting the stock to turn back up later this month.

Charts Provided Courtesy Of TradePortal.com

The OTC Journal is a proud partner of the SwingWire.com Online Investment Community. A next generation Online Analyst Exchange providing Members the ability to search, review, track and monitor some of the Internet's best Online CAs (CyberAnalysts). Members have the opportunity to potentially achieve higher returns by viewing top performing portfolios and receiving real-time alerts from favorite CAs.

SwingWire.com also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts!

Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today!

Disclaimer

The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter is owned by MarketByte, LLC. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.

Click Here to view our compensation on every company we have ever covered, or visit the following web address: http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $100,000 in cash and 100,000 options exercisable at $2.50 by the Investor Relations Group for publishing information on Astralis LLC for a period of one year. Fifty thousand options are exercisable immediately, and fifty thousand become eligible on April 1, 2002.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which the editors are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to http://listserv.otcjournal.com/opt.cgi?.